Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 26 min ago
Peer-reviewedCC BY-NCJournal for immunotherapy of cancer

Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.

  • Xiaojing Wu1
  • Clara Effenberger2
  • Yosuke Matsushita3
  • Hiroki Tanaka4
  • Yu Ishii1
  • Suyong Re5
  • Saki Matsumoto2
  • Satoshi Nagayama1,6,7
  • Yusuke Nakamura1
  • Kazuma Kiyotani8
8 affiliations
  1. 1Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka, Japan.
  2. 2Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  3. 3Laboratory of Biofunctional Molecular Medicine, Center for Drug Design Research (CDDR), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka, Japan.
  4. 4Laboratory of Molecular Diagnostics and Therapeutics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka, Japan.
  5. 5Laboratory of In Silico Design, Artificial Intelligence Center for Health and Biomedical Research (ArCHER), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka, Japan.
  6. 6Department of Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan.
  7. 7Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  8. 8Laboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Ibaraki, Osaka, Japan [email protected].
Read full textPDFDOICite

Related

  1. 989 Beyond CRS: emerging longitudinal safety management strategies for T-cell–engaging bispecific antibodies
    Nicholas A Zorko, Rifeta Kajdic Hodzic, Kirollos S Hanna +12
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. CD3-engaging bispecific antibodies convert human regulatory T cells into cytotoxic effectors
    J. J. Michel, J. H. Frenking, A. Metzler +23
    medRxivPreprintAll rights reservedFull textOncologymedRxiv
  3. Neurologist-focused workflows for immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy and CD3-engaging bispecific antibodies
    Walid Alesefir, Mariam Hejazi, Basil Alashger +6
    Frontiers in NeurologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  4. Bispecific antibodies targeting TL1A and IL-12/23p40 suppress pathogenic Th1/Th17 responses and ameliorate colitis in mice
    Xia Li, Hao Peng, Feng Hao +3
    iSciencePeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCell PressCrossrefEurope PMC
  5. Bispecific antibodies targeting B‐cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions
    Enrica Manzato, Gloria Cocchetto, Simona Barbato +3
    CancerPeer-reviewedCC BY 4.0Full textGeneral medicinePMC

Cite

BibTeXRIS
BibTeX
@article{wu2026engineering,
  title = {{Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.}},
  author = {Xiaojing Wu and Clara Effenberger and Yosuke Matsushita and Hiroki Tanaka and Yu Ishii and Suyong Re and Saki Matsumoto and Satoshi Nagayama and Yusuke Nakamura and Kazuma Kiyotani},
  journal = {Journal for immunotherapy of cancer},
  year = {2026},
  month = oct,
  doi = {10.1136/jitc-2026-016411},
  url = {https://europepmc.org/article/MED/42896875},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01.
AU  - Xiaojing Wu
AU  - Clara Effenberger
AU  - Yosuke Matsushita
AU  - Hiroki Tanaka
AU  - Yu Ishii
AU  - Suyong Re
AU  - Saki Matsumoto
AU  - Satoshi Nagayama
AU  - Yusuke Nakamura
AU  - Kazuma Kiyotani
PY  - 2026
DA  - 2026/10/18
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2026-016411
UR  - https://europepmc.org/article/MED/42896875
SN  - 2051-1426
ER  -